Latest news with #EliLilly
Bloomberg
30 minutes ago
- Business
- Bloomberg
Hengrui's Obesity Drug Rivals Zepbound in Late-Stage China Trial
Jiangsu Hengrui Pharmaceuticals Co. and its US partner said their obesity drug candidate succeeded in a late-stage China study, a key step toward securing approval as domestic biotech firms increasingly challenge foreign rivals. Chinese patients taking the drug from Hengrui and Kailera Therapeutics lost up to 17.7% of their weight on average, the companies said in a statement this week. When adjusted for the placebo group, the drop in weight came in at 16.3% — a reduction comparable to what Eli Lilly & Co.'s Zepbound once showed in its China trial.
Economic Times
8 hours ago
- Health
- Economic Times
ET Graphics: Weight loss drugs Tirzepatide, Semaglutide dominate India, misuse fears rise
Tirzepatide and semaglutide dominate India's anti-obesity drug market, holding a 75% share. While seen as vital tools by doctors, experts caution against misuse, particularly among young adults. Aggressive marketing and social media trends are fueling peer pressure, potentially leading to inappropriate use of these weight-loss medications. Tired of too many ads? Remove Ads New-age weight-loss molecules have taken over the anti-obesity drug market in India , with tirzepatide and semaglutide (generic names) collectively occupying 75% of the market see Eli Lilly's Mounjaro and Novo Nordisk's Wegovy as important ammunitions in the anti-obesity experts also point out the risk of the drug being misused by many — especially young adults — amplied by aggressive marketing, widespread social media promotions and a growing peer pressure driven by the weight loss fad.
Time of India
9 hours ago
- Health
- Time of India
ET Graphics: Weight loss drugs Tirzepatide, Semaglutide dominate India, misuse fears rise
New-age weight-loss molecules have taken over the anti-obesity drug market in India , with tirzepatide and semaglutide (generic names) collectively occupying 75% of the market share. Doctors see Eli Lilly's Mounjaro and Novo Nordisk's Wegovy as important ammunitions in the anti-obesity treatment. However, experts also point out the risk of the drug being misused by many — especially young adults — amplied by aggressive marketing, widespread social media promotions and a growing peer pressure driven by the weight loss fad. by Taboola by Taboola Sponsored Links Sponsored Links Promoted Links Promoted Links You May Like Discover Effortless Glucose Monitoring: Request a Free Trial Dexcom Click Here Undo
Business Insider
a day ago
- Business
- Business Insider
Eli Lilly (LLY) Expects Results from Weight-Loss Pill Trial by Sept. 30
Pharmaceutical giant Eli Lilly (LLY) says that it expects the clinical trial results of its experimental weight-loss pill called Orforglipron to be released by the end of the current third quarter that runs until Sept. 30. Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week. The weight-loss pill is aimed at helping people lose weight and lower their blood sugar. Management at Eli Lilly says they aim to announce within the current quarter, the trial results for the drug that is being tested in overweight and obese people. Eli Lilly says that it plans to submit the non-diabetes Phase 3 clinical trial data to global regulatory agencies by the end of the year, and seek approval to begin selling the medication on a commercial basis in the U.S. and other jurisdictions. The U.S. Food and Drug Administration (FDA) typically makes new drug approval decisions 10 months after a pharmaceutical company makes a submission or application for regulatory approval. Game-Changer? Many analysts who follow LLY stock expect the approval of the weight-loss pill to be a game-changer for the company and the entire weight-loss industry. Currently, weight-loss medications are taken by injection that involves people administering needles to themselves. A once per day pill is seen as a much more palatable way for people to take weight-loss drugs, say analysts. Wall Street investment bank Morgan Stanley (MS) recently forecast that the global market for weight-loss medications could reach $150 billion by 2035, with much of that growth coming from pill versions of the prescription drugs. Is LLY Stock a Buy? The stock of Eli Lilly has a consensus Strong Buy rating among 19 Wall Street analysts. That rating is based on 16 Buy, two Hold, and one Sell recommendations issued in the last 12 months. The average LLY price target of $1,006.80 implies 26.36% upside from current levels.
Yahoo
2 days ago
- Business
- Yahoo
Market to Reach $14.34 Billion by 2034, Driven by Innovative R&D, Strategic Collaborations, and Drug Formulation Advancements
The Europe GLP-1 agonists market, valued at USD 7.09 billion in 2024, is set to grow at a 17.30% CAGR, reaching USD 14.34 billion by 2034. Driven by rising diabetes and obesity rates, innovative drug formulations, and supportive healthcare policies, the market is expanding. Key players include Eli Lilly, Sanofi, and Novo Nordisk. Challenges involve high costs and regulatory complexities. Opportunities lie in obesity treatment expansion and advanced drug delivery systems. European Glucagon-like Peptide-1 (GLP-1) Agonists Market Dublin, July 14, 2025 (GLOBE NEWSWIRE) -- The "Europe Glucagon-like Peptide-1 (GLP-1) Agonists Market Report and Forecast 2025-2034" has been added to offering. The Europe glucagon-like peptide-1 (GLP-1) agonists market is projected to witness significant growth, fueled primarily by an increased prevalence of type 2 diabetes and obesity. Originally valued at USD 7.09 billion in 2024, the market is estimated to expand at a compound annual growth rate (CAGR) of 17.30%, expecting a valuation of USD 14.34 billion by 2034. The competitive landscape features major pharmaceutical firms like Novo Nordisk, Eli Lilly, Sanofi, AstraZeneca, and others focused on innovative R&D, strategic collaborations, and drug formulation advancements. These companies aim to enhance market presence through mergers, acquisitions, and partnerships that promote access and compliance, ensuring sustained growth in the Europe's GLP-1 agonists market. The market's expansion is propelled by the increasing incidence of diabetes and obesity, augmented by sedentary lifestyles and poor dietary choices. GLP-1 agonists, as incretin-based therapies, are preferred for their efficacy in controlling blood sugar levels and facilitating weight loss, crucial aspects in managing diabetes and obesity. The growth trajectory is supported by rising healthcare expenditure, a burgeoning elderly demographic, advancements in drug delivery, and a robust regulatory framework favoring novel therapeutic adoption. Key Attributes: Report Attribute Details No. of Pages 300 Forecast Period 2025 - 2034 Estimated Market Value (USD) in 2025 $7.09 Billion Forecasted Market Value (USD) by 2034 $14.34 Billion Compound Annual Growth Rate 7.3% Regions Covered Europe Market Drivers A surge in type 2 diabetes and obesity cases. Favorable government initiatives and reimbursement policies bolstering access to innovative treatments. Improved drug formulations like once-weekly injectables and oral options enhancing patient compliance. A growing trend towards combination therapies integrating GLP-1 agonists for optimized results. Market Challenges High costs of GLP-1 therapies affecting widespread accessibility. Potential side effects that could hinder patient adherence. Regulatory complexities delaying new therapy commercializations. Future Opportunities Expanding applications in obesity treatment beyond diabetes management. Innovative drug delivery system developments heightening market penetration. Strategic R&D investments for next-gen GLP-1 therapies with enhanced efficacy. Europe GLP-1 Agonists Market Trends The shift towards long-acting GLP-1 formulations like once-weekly injections elevating patient compliance. The increasing use of GLP-1 agonists in obesity management, supported by regulatory endorsements. Clinical validation of cardiovascular benefits driving GLP-1 adoption among patients at cardiovascular risk. Policymaker efforts in expanding healthcare coverage improving treatment accessibility. The development of multi-target GLP-1 therapies promises superior management of diabetes and weight issues. Strategic collaborations in biosimilar production broadening market access and affordability. Market Segmentation By Drugs: Key drugs include dulaglutide, exenatide, liraglutide, tirzepatide, lixisenatide, and semaglutide. By Application: The applications span type 2 diabetes mellitus and obesity treatment. By Route of Administration: Dominated by parenteral routes, the market is gradually seeing a rise in oral solution adoption. By End User: Primary users are hospitals, specialty clinics, academic research sites, with home care settings gaining traction. By Distribution Channel: Hospital pharmacies prevail, while retail and online pharmacies steadily gain ground. By Region: The United Kingdom, Germany, France, and Italy emerge as principal markets, bolstered by strong infrastructure and supportive policies. Companies Featured Eli Lilly and Company Sanofi Novo Nordisk A/S AstraZeneca plc For more information about this report visit About is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends. Attachment European Glucagon-like Peptide-1 (GLP-1) Agonists Market CONTACT: CONTACT: Laura Wood,Senior Press Manager press@ For E.S.T Office Hours Call 1-917-300-0470 For U.S./ CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
